Hereditary Angioedema Treatments
Therapeutic Class Review (TCR)

December 1, 2021

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management.

All requests for permission should be mailed to:

Magellan Rx Management
Attention: Legal Department
6950 Columbia Gateway Drive
Columbia, Maryland 21046

The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to PSTCREditor@magellanhealth.com.
FDA-APPROVED INDICATIONS

<table>
<thead>
<tr>
<th>Drug</th>
<th>Manufacturer</th>
<th>Indication(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>berotralstat (Orladeyo™)</td>
<td>BioCryst</td>
<td>Routine prophylaxis to prevent HAE attacks in ages ≥ 12 years</td>
</tr>
<tr>
<td>C1-esterase INH [Human] (Cirnryze™)</td>
<td>Viropharma</td>
<td>Routine prophylaxis to prevent HAE attacks in ages ≥ 6 years</td>
</tr>
<tr>
<td>C1-esterase INH [Human] (Haegarda™)</td>
<td>CSL Behring</td>
<td>Routine prophylaxis to prevent HAE attacks in ages ≥ 6 years</td>
</tr>
<tr>
<td>lanadelumab-flyo (Takhzyro™)</td>
<td>Dyax/Shire</td>
<td>Routine prophylaxis to prevent HAE attacks in ages ≥ 12 years</td>
</tr>
<tr>
<td>ecallantide (Kalbitor*)</td>
<td>Dyax/Shire</td>
<td>Treatment of acute HAE attacks in ages ≥ 12 years</td>
</tr>
<tr>
<td>icatibant (Firazyr®)</td>
<td>generic, Shire</td>
<td>Treatment of acute HAE attacks in ages ≥ 18 years</td>
</tr>
<tr>
<td>C1-esterase INH [Human] (Berinert®)</td>
<td>CSL Behring</td>
<td>Treatment of acute HAE facial, laryngeal, or abdominal attacks in adult and pediatric patients Safety and efficacy for prophylactic therapy have not been established</td>
</tr>
<tr>
<td>rhC1-INH [recombinant] (Ruconest®)</td>
<td>Santarus/Pharming Healthcare</td>
<td>Treatment of acute attacks in adult and adolescent patients with HAE Effectiveness has not been established in HAE patients with laryngeal attacks</td>
</tr>
</tbody>
</table>

C1-INH = C1 esterase inhibitor; HAE = hereditary angioedema
Berinert, Cirnryze, and Haegarda are plasma-derived (pd) C1 esterase inhibitors. Ruconest is a recombinant (rh) analogue of human complement C1 esterase inhibitor.

OVERVIEW

Hereditary angioedema (HAE) is a rare, dominant autosomal genetic disorder that affects approximately 6,000 individuals in the United States (US). Patients with HAE have low levels of endogenous or functional C1 esterase inhibitor (C1-INH). HAE is characterized by recurrent episodes of nonpruritic, nonpitting, subcutaneous (SC) or submucosal edema involving the skin or mucosal tissues of the upper respiratory and gastrointestinal (GI) tracts. Although swelling can resolve spontaneously in several days, without treatment laryngeal edema may be fatal and the pain of GI attacks can be incapacitating. Symptoms can begin as early as 2 years of age and persist throughout life with unpredictable severity and frequency of attacks. It is thought that minor trauma and stress can lead to an attack; however, many attacks occur without any apparent trigger. There are 2 types of C1-INH deficient HAE. The most common type (Type I), in which the body does not produce enough C1-INH, occurs in about 85% of patients with the condition. Type II HAE is characterized by the presence of normal or high levels of a dysfunctional C1-INH.

The complications of HAE do not respond well to the usual therapies for mast cell-mediated angioedema, including antihistamines, epinephrine, and glucocorticosteroids, necessitating the establishment of an accurate diagnosis. Plasma complement protein 4 (C4) antigenic levels should be measured in any
patients suspected of having HAE. C1-Inhibitor antigenic and functional levels should be tested to confirm the HAE diagnosis if the C4 level is decreased and in cases where C4 level is normal and most or all the clinical criteria listed above are met.

HAE prophylaxis is needed to reduce potential edema caused by a stressor or procedure likely to precipitate an attack (short-term prophylaxis) or to decrease the number and severity of angioedema attacks (long-term prophylaxis). The 2020 US Hereditary Angioedema Association (HAEA) guidelines for the management of HAE recommends short-term prophylaxis prior to medical, dental, or surgical procedures. The need for long-term prophylaxis should be made based on attack frequency, attack severity, comorbid conditions, access to treatment, and patient experience and preference. As disease severity may change over time, the need for continued long-term prophylaxis should be assessed periodically. In addition, patients receiving prophylactic therapy should also have access to on-demand treatment for acute attacks.

The 2020 US HAEA guidelines provides recommendations to help with recognition, diagnosis, treatment of attacks, and prophylaxis. These recommendations state that an accurate diagnosis of HAE must be established prior to discussing treatment options. An accurate diagnosis may be accomplished by measurement of serum C4 and assessment of C1-INH activity (functional and quantitative). Additionally, treatment strategies should be individualized based primarily on patient specific factors such as age, comorbidities, and access to emergency medical facilities. The goal of treatment in children with HAE is to prevent mortality, minimize morbidity, and to allow for a normal childhood. The guidelines include 4 guiding principles: available on-demand acute therapy for all patients, early treatment to prevent attack progression, treatment of attack irrespective of the site of swelling, and individualized long-term prophylaxis. The guidelines recommend a single dose of plasma-derived (pd)C1-INH (Cinryze or Haegarda) or a course of anabolic androgen as the treatment of choice for children and adults for short-term prophylaxis prior to medical, surgical, or dental procedures. For long-term prophylaxis in children and adults, the guidelines recommend intravenous pdC1-INH (Cinryze), subcutaneous pdC1-INH (Haegarda), and the monoclonal antibody lanadelumab-flyo (Takhzyro), a plasma kallikrein inhibitor, as first-line therapy. If first-line therapy is not available or the patient will only accept oral therapy, anabolic androgen and antifibrinolytics can be utilized as second-line treatment options. For on-demand acute therapy in children and adults, the guidelines recommend one of the 4 medications FDA approved for use to treat HAE attacks: intravenous pdC1-INH (Berinert), intravenous recombinant human (rh)C1-INH (Ruconest), subcutaneous plasma kallikrein inhibitor ecallantide (Kalbitor), and the subcutaneous bradykinin B2 receptor antagonist icatibant (Firazyr). Berotralstat (Orladeyo) was approved after the 2020 US HAEA guidelines were published and therefore is not included in the recommendations.

An international consensus group, which included representation from the US, recommended the use of plasma-derived human C1-INH (Berinert, Cinryze) for acute treatment, short-term prophylaxis, and long-term prophylaxis in pregnant patients and stated this should also be available during labor and delivery, if needed. Tranexamic acid or fresh frozen plasma (FFP) may be used for long-term prophylaxis if plasma-derived human C1-INH is unavailable. Data in this population using recombinant C1-INH (Ruconest) were not available at the time of this publication. Traditionally, 17-alpha-alkylated androgens (e.g., danazol) have been used for HAE prophylaxis. This oral anabolic androgen is associated with many adverse effects and is contraindicated in pediatrics and pregnancy/lactation. The HAEA evidence-based recommendations advise against the use of anabolic androgens for long-term prophylaxis for patients who are intolerant to anabolic androgen or if the effective dose exceeds the equivalent of 200 mg danazol per day. Also, failure of androgen therapy should not be a prerequisite to prophylactic C1-INH
therapy. Antifibrinolytic agents (e.g., tranexamic acid and aminocaproic acid) have also been used to prevent HAE attacks but have limited efficacy and significant toxicity. C1-INH (Cinryze) has demonstrated effectiveness in short- and long-term prophylaxis. Haegarda, Takhzyro, and Orladeyo were not available at the time of this guideline’s development.

In 2017, an international consensus group provided guidance on the diagnosis and management of pediatric patients with C1-INH HAE. Symptoms of C1-INH HAE often are first seen in childhood and the differential diagnosis can be difficult to determine since abdominal pain is common in the general pediatric population. A more severe course of the disease may be foreseen by the early onset of symptoms. All neonates/infants with an affected C1-INH HAE family member should be screened for C1-INH deficiency. Confirmation of the diagnosis should be made after 1 year of age since C1-INH levels may be lower than in adults before this time. Patients’ care should be followed at an HAE comprehensive care center. Therapeutic prophylaxis includes either short-term prophylaxis before a precipitating event or long-term prophylaxis. As in adults, indications for short-term prophylaxis in pediatrics include patient-specific triggers and medical and dental procedures. For most minor interventions, the group recommends on-demand treatment if a swelling event occurs instead of prophylaxis treatment (Level III evidence). For interventions requiring airway manipulation or that may precipitate tissue swelling, prophylaxis with a dose of 15 to 30 units per kg pdC1-INH (Berinert) is recommended (Level III evidence). In the event that approved short-term prophylaxis HAE treatment is not available with a planned procedure, oral attenuated androgens (e.g., danazol) or antifibrinolytics (e.g., tranexamic acid) may be considered, starting at least 5 days before and continued for 2 days after the procedure (Level III evidence); approved on-demand treatment should be made available in case of failure. Long-term prophylaxis is controversial in adults and pediatrics and may be considered to maximize quality of life. Agents to consider include antifibrinolytics (tranexamic acid is the agent of choice in select patients), attenuated androgens, and pdC1-INH. The consensus group states that pdC1-INH may be the safest option for long-term prophylaxis and recommends this treatment over attenuated androgens. For acute treatment, they give no preference to one pediatric use-approved drug over another. Haegarda, Takhzyro, and Orladeyo were not available at the time of this guideline development.

The 2017 World Allergy Organization (WAO) and European Academy of Allergy and Clinical Immunology (EAACI) issued an update to the 2012 guidelines on the management of HAE. The revised guidelines recommended C1-INH (Berinert, Cinryze, Haegarda, and Ruconest) as first line agents for long-term prophylaxis; androgens are suggested as second-line long-term prophylaxis. The guidelines also recommend that HAE attacks be treated with either C1-INH (Berinert, Cinryze, Haegarda, and Ruconest), ecallantide (Kalbitor), or icatibant (Firazyr). No one agent is recommended over another. If the aforementioned agents are not available, solvent detergent-treated plasma (SDP) should be used; if SDP is not available, fresh frozen plasma (FFP) can be used. Antifibrinolytics (tranexamic acid) or androgens (danazol) should not be used for on-demand treatment of HAE attacks due to no or minimal benefit. Takhzyro and Orladeyo were not available at the time of this guideline development.

**PHARMACOLOGY**

HAE is caused by mutations in the C1-INH located on chromosome 11q and is characterized by low levels of C1-INH activity and low levels of C4. C1-INH functions to regulate the activation of the complement and intrinsic coagulation (contact system pathway) and is a major endogenous inhibitor of plasma kallikrein. The kallikrein-kinin system is a complex proteolytic cascade involved in the initiation of both inflammatory and coagulation pathways. One critical aspect of this pathway is the conversion of high
molecular weight (HMW) kininogen to bradykinin by the protease plasma kallikrein. In HAE, normal regulation of plasma kallikrein activity and the classical complement cascade is not present; thus, during HAE attacks, unregulated activity of plasma kallikrein results in excessive bradykinin generation. Bradykinin is a vasodilator which is thought to be responsible for the characteristic HAE symptoms, including localized swelling, inflammation, and pain.

Berinert, Cinryze, and Haegarda are human plasma-derived, purified, pasteurized, lyophilized concentrates of C1-INH. Ruconest is a recombinant analogue of C1-INH purified from the milk of transgenic rabbits. C1-INH acts by inhibiting kallikrein and suppressing bradykinin formation resulting in increased plasma levels of C1-INH activity. All 3 C1-INH products are intravenously (IV) administered. Nontherapeutic proteins may be found in these products, but the impact of these proteins on safety, such as immunogenicity and efficacy, is unknown. Purity may also play a role in immunogenicity; purity was highest for rhC1-INH (Ruconest) (98.6%), followed by the plasma-derived C1-INH, Berinert (97%) and Cinryze (89.5%).

Haegarda was not available at the time this comparison was made.

Ecallantide (Kalbitor) is a recombinant selective, reversible inhibitor of the plasma protein kallikrein. When ecallantide binds to kallikrein the conversion of HMW kininogen to bradykinin is blocked. Ecallantide is administered subcutaneously by a healthcare professional (HCP). Lanadelumab-flyo (Takhzyro) is also a kallikrein inhibitor, but it is a fully human monoclonal antibody. When lanadelumab-flyo binds to plasma kallikrein, it inhibits its proteolytic activity. Lanadelumab-flyo is self-administered SC. Berotralstat (Orladeyo) is an oral plasma kallikrein inhibitor and inhibits the proteolytic activity of plasma kallikrein, thus lowering excess bradykinin production in HAE patients.

Icatibant (Firazyr) is a selective synthetic bradykinin B2 receptor antagonist. Icatibant has similar receptor affinity as bradykinin. Icatibant is self-administered SC.

### PHARMACOKINETICS

<table>
<thead>
<tr>
<th>Drug</th>
<th>Cmax</th>
<th>Tmax (hr)</th>
<th>Half-life (hr)</th>
<th>Metabolism</th>
<th>Excretion (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>berotralstat (Orladeyo)</td>
<td>158 ng/mL</td>
<td>5</td>
<td>39-152</td>
<td>CYP2D6; CYP3A4</td>
<td>feces: 79</td>
</tr>
<tr>
<td>ecallantide (Kalbitor)</td>
<td>586 ng/mL</td>
<td>2-3</td>
<td>2</td>
<td>nr</td>
<td>renal</td>
</tr>
<tr>
<td>icatibant (Firazyr)</td>
<td>974 ng/mL</td>
<td>0.75</td>
<td>1.4</td>
<td>extensively metabolized by proteolytic enzymes to inactive metabolites</td>
<td>renal</td>
</tr>
<tr>
<td>pdC1-INH [Human] (Berinert)</td>
<td>nr</td>
<td>nr</td>
<td>24</td>
<td>nr</td>
<td>nr</td>
</tr>
<tr>
<td>pdC1-INH [Human] (Cinryze)</td>
<td>0.68-0.85 units/mL</td>
<td>2.7-3.9</td>
<td>56-62</td>
<td>nr</td>
<td>nr</td>
</tr>
<tr>
<td>pdC1-INH [Human] (Haegarda)</td>
<td>60.7 (%)</td>
<td>59</td>
<td>69</td>
<td>nr</td>
<td>nr</td>
</tr>
<tr>
<td>lanadelumab-flyo (Takhzyro)*</td>
<td>34.4 µg/mL</td>
<td>98</td>
<td>360</td>
<td>nr</td>
<td>nr</td>
</tr>
<tr>
<td>rhC1-INH [recombinant] (Ruconest)</td>
<td>1.2-1.3 IU/mL</td>
<td>0.3</td>
<td>2.4-2.7</td>
<td>nr</td>
<td>nr</td>
</tr>
</tbody>
</table>

Cmax = maximum serum concentration; Tmax = time to maximum serum concentration
* Lanadelumab-flyo (Takhzyro) pharmacokinetics based on the 300 mg every 2 week dosing interval
CONTRAINDICATIONS/WARNINGS\textsuperscript{37,38,39,40,41,42,43,44}

C1-INH products (Berinert, Cinryze, Haegarda, Ruconest) are contraindicated in patients with known serious hypersensitivity to the product. Hypersensitivity reactions may include hives, urticaria, tightness of chest, wheezing, and hypotension. If hypersensitivity reaction is suspected, C1-INH should be discontinued, and treatment of hypersensitivity reactions should be carefully considered since symptoms are similar to HAE. Epinephrine should be prescribed for patients on C1-INH therapy for immediate use for acute severe hypersensitivity reactions.

Recombinant C1-INH (Ruconest) is also contraindicated in patients with a known allergy to rabbits or rabbit-derived products.

Use of ecallantide (Kalbitor) is contraindicated in patients with a known hypersensitivity to the product. Boxed warnings advise that ecallantide should only be administered by an HCP with appropriate medical support to manage anaphylaxis and HAE. Patients should be observed for an appropriate period of time after administration of ecallantide.

There are no contraindications reported for icatibant (Firazyr), lanadelumab-flyo (Takhzyro), or berotralstat (Orladeyo).

Thromboembolic events (TE) have been reported in patients receiving C1-INH. Risk factors for TE include presence of an indwelling venous catheter, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptive or androgen therapy, morbid obesity, and immobility.

Since plasma-derived C1-INH agents (Berinert, Cinryze, Haegarda) are derived from human blood, there is a potential for transmission of infection.

In addition to self-administering acute treatment with C1-INH (Berinert, Haegarda) or icatibant (Firazyr) for an acute HAE attack, patients should be instructed to seek immediate medical attention if laryngeal involvement is present.

The B2 receptor has been associated with cardioprotective effects of bradykinin and antagonism of this receptor has the potential to result in negative cardiovascular effects after acute ischemia. Icatibant (Firazyr) should be used with caution in patients with unstable angina and acute coronary ischemia and during the weeks following a cerebrovascular accident.

Hypersensitivity reactions have been reported with lanadelumab-flyo. The product should be discontinued if a severe reaction occurs.

Increases in the QT interval have been reported with berotralstat if used at dosages higher than the recommended 150 mg once daily; QT prolongation was concentration dependent.

DRUG INTERACTIONS\textsuperscript{45,46,47,48,49,50,51,52}

No drug interaction studies have been performed with C1-INH (Berinert, Cinryze, Haegarda, Ruconest) or ecallantide (Kalbitor).

Icatibant (Firazyr) has the potential to increase the antihypertensive effects of angiotensin converting enzyme (ACE) inhibitors.
No drug interaction studies have been conducted with lanadelumab-flyo. Due to an interaction with the test assay, lanadelumab-flyo can increase activated partial thromboplastin time (aPTT); this is not associated with abnormal bleeding. International normalized ratio (INR) is not affected.

Berotralstat (Orladeyo) is a P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) substrate. For patients on P-gp or BCRP inhibitors (e.g., cyclosporine), a decreased dose of berotralstat is recommended. Berotralstat is not recommended with P-gp inducers (e.g., rifampin, St. John’s wort) due to reduced efficacy. Berotralstat is a moderate inhibitor of cytochrome P450 (CYP) 2D6 and CYP3A4; therefore, careful monitoring and dose titration is recommended for medications with a narrow therapeutic index that are predominantly metabolized via these pathways. At a dose of 300 mg, berotralstat is a P-gp inhibitor; monitoring and dose titration should occur for concurrently administered P-gp substrates (e.g., digoxin).

ADVERSE EFFECTS

<table>
<thead>
<tr>
<th>Drug</th>
<th>Headache</th>
<th>Nausea</th>
<th>Rash</th>
<th>Vomiting</th>
<th>Abdominal Pain</th>
<th>Pyrexia</th>
<th>Injection Site Reaction</th>
<th>Diarrhea</th>
</tr>
</thead>
<tbody>
<tr>
<td>berotralstat (Orladeyo)</td>
<td>9 (5)</td>
<td>nr</td>
<td>&lt; 1%</td>
<td>15 (3)</td>
<td>23 (10)</td>
<td>nr</td>
<td>na</td>
<td>15 (0)</td>
</tr>
<tr>
<td>ecallantide (Kalbitor)</td>
<td>11</td>
<td>13</td>
<td>3</td>
<td>6</td>
<td>5</td>
<td>5</td>
<td>3-7</td>
<td>11</td>
</tr>
<tr>
<td>icatibant (Firazyr)</td>
<td>reported</td>
<td>reported</td>
<td>reported</td>
<td>nr</td>
<td>nr</td>
<td>4 (0)</td>
<td>97 (25)</td>
<td>nr</td>
</tr>
<tr>
<td>pdC1-INH [Human] (Berinert)</td>
<td>7 (11.9)</td>
<td>7 (26.2)</td>
<td>3.5</td>
<td>2.3 (16.1)</td>
<td>7 (11.9)</td>
<td>nr</td>
<td>reported</td>
<td>0 (19)</td>
</tr>
<tr>
<td>pdC1-INH [Human] (Cinryze)</td>
<td>19</td>
<td>18</td>
<td>10</td>
<td>10</td>
<td>nr</td>
<td>5</td>
<td>reported</td>
<td>nr</td>
</tr>
<tr>
<td>pdC1-INH [Human] (Haegarda)</td>
<td>nr</td>
<td>nr</td>
<td>reported</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>28-35 (24)</td>
<td>nr</td>
</tr>
<tr>
<td>lanadelumab-flyo (Takhzyro)</td>
<td>9 (33)</td>
<td>nr</td>
<td>1 (4)</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>15 (56)</td>
<td>1 (4)</td>
</tr>
<tr>
<td>rhC1-INH [recombinant] (Ruconest)</td>
<td>9</td>
<td>2</td>
<td>reported</td>
<td>nr</td>
<td>≥2</td>
<td>nr</td>
<td>nr</td>
<td>2</td>
</tr>
</tbody>
</table>

Adverse effects are reported as a percentage. Incidences for the placebo group are indicated in parentheses. nr = not reported. na = not applicable.

Other common adverse reactions reported for ecallantide (Kalbitor) include fatigue (12%), upper respiratory tract infection (8%), and nasopharyngitis (6%). In clinical studies, serious thrombotic adverse events were observed with pdC1-INH (Cinryze), including cerebrovascular accident (< 1%).
The most common adverse reactions that occurred in at least 4% of C1-INH (Haegarda) patients included injection site reactions, hypersensitivities, nasopharyngitis, and dizziness.

Because C1-INH (Berinert, Cinryze, Haegarda, Ruconest), is a therapeutic protein, there is potential for immunogenicity; however, no anti-C1 esterase inhibitor antibodies have been detected. There is no evidence that resistance develops with C1-INH treatment.

Presence of antibodies to ecallantide (Kalbitor) has been reported in approximately 20% of patients treated with ecallantide. Neutralizing antibodies were discovered in 8.8% of patients and did not lead to reduced efficacy. Rates of seroconversion increase with increased exposure to ecallantide and patients who seroconvert may be at increased risk of hypersensitivity reactions.

In clinical studies, anti-icatibant antibodies were detected in 4 patients, of which 3 patients had subsequent negative tests for antibodies. No change in efficacy or incidence of hypersensitivity was observed.

Another common adverse reaction reported for lanadelumab-flyo (Takhzyro) is upper respiratory tract infection (31% to 44%). Anti-drug antibodies (ADA) were reported more often in patients who received lanadelumab-flyo than placebo (12% versus 5%); however, the development of ADA, including neutralizing antibodies against lanadelumab-flyo, did not adversely affect the safety or efficacy of lanadelumab-flyo.

Other common adverse reactions (≥ 5%) reported for berotralstat compared to placebo, respectively, included back pain (6% versus 3%), fatigue (6% versus 3%), flatulence (6% versus 3%), and gastroesophageal reflux disease (7% versus 0).

**SPECIAL POPULATIONS**61,62,63,64,65,66,67,68

**Pediatrics**

The safety and efficacy of pdC1-INH (Cinryze) was studied and approved for adults, adolescents and pediatric patients ≥ 6 years of age. The safety profile of C1-INH (Berinert) in the pediatric population was found to be similar to that observed in adults. The safety and effectiveness of C1-INH (Haegarda) was studied and approved for adults, adolescents, and pediatric patients ≥ 6 years of age. Recombinant C1-INH (Ruconest) is indicated for use in adolescents and was studied in patients ≥ 13 years.

Ecallantide (Kalbitor) is approved for use in patients ≥ 12 years of age. Data on the effectiveness of ecallantide in 12 to 15 year old patients, which showed similar drug exposure in adult and adolescent patients, were extrapolated to patients ≥ 16 years of age.

Safety and efficacy of icatibant (Firazyr) have not been established in patients < 18 years of age.

Lanadelumab-flyo (Takhzyro) and berotralstat (Orladeyo) are approved for use in patients ≥ 12 years of age.

**Geriatrics**

The number of subjects ≥ 65 years of age in studies of pdC1-INH (Berinert, Cinryze), rhC1-INH (Ruconest), ecallantide (Kalbitor), and icatibant (Firazyr) were not sufficient to establish differing response from younger patients. The safety and efficacy of Haegarda were evaluated in a subgroup of patients aged 65 to 72 years (n=8); results were consistent with the overall study group. The safety and efficacy of lanadelumab-flyo (Takhzyro) were evaluated in a subgroup of patients ≥ 65 years of age (n=5), and the
results were consistent with the overall study group. The safety and efficacy of berotralstat (Orladeyo) were evaluated in a subgroup of patients ≥ 65 years of age (n=9), and the results were consistent with the overall study group.

Pregnancy

Plasma-derived C1-INH (Berinert, Cinryze, Haegarda) is Pregnancy Category C since no animal data are available. There are no adequate and well controlled studies available to assess the use of C1-INH (Haegarda and Ruconest) during pregnancy. However, C1-INH is a normal component of plasma. Ecallantide (Kalbitor), previously Pregnancy Category C, and icatibant (Firazyr) have not shown a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes based on published literature and the pharmacovigilance database. No data are available on the use of lanadelumab-flyo (Takhzyro) in pregnant women. Monoclonal antibodies such as lanadelumab-flyo cross the placenta during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy. There are insufficient data on the use of berotralstat (Orladeyo) in pregnant women to determine drug-related risks.

Hepatic Impairment

No dose adjustment of icatibant (Firazyr) is needed in patients with hepatic impairment.

Use of C1-INH (Berinert, Cinryze, Haegarda, Ruconest) in patients with hepatic impairment has not been evaluated.

No pharmacokinetic data are available for use of ecallantide (Kalbitor) and lanadelumab-flyo (Takhzyro) in patients with hepatic impairment.

No dose adjustment of berotralstat (Orladeyo) is needed in patients with mild hepatic impairment. For those with moderate to severe hepatic impairment (Child-Pugh B or C), the recommended dose is 110 mg once daily.

Renal Impairment

No dose adjustment of icatibant (Firazyr) is needed in patients with renal impairment.

Use of C1-INH (Berinert, Cinryze, Haegarda, Ruconest) in patients with renal impairment has not been evaluated.

No pharmacokinetic data are available for use of ecallantide (Kalbitor) and lanadelumab-flyo (Takhzyro) in patients with renal impairment.

No dose adjustment of berotralstat (Orladeyo) is needed in patients with mild, moderate, or severe renal impairment. Berotralstat has not been studied in patients with End-Stage Renal Disease (ESRD), and therefore is not recommended in this population.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prophylaxis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>berotralstat (Orladeyo)</td>
<td>150 mg orally once daily with food; 110 mg once daily with food can be given for persistent gastrointestinal reactions</td>
<td>110 mg and 150 mg capsule</td>
</tr>
<tr>
<td>pdC1-INH (Cinryze)</td>
<td>6 to 11 years of age: 500 units IV every 3 to 4 days infused at a rate of 1 mL/min (5 minutes); Age ≥ 12 years: 1,000 units IV every 3 to 4 days at a rate of 1 mL/min (10 minutes); If no response to the above routine prophylaxis dosing: doses up to 2,500 units (U) (not exceeding 100 U/kg) every 3 to 4 days may be considered based on individual response; May be self-administered with proper training</td>
<td>Lyophilized powder for reconstitution; 500 units/5 mL single-use vial</td>
</tr>
<tr>
<td>pdC1-INH (Haegarda)</td>
<td>60 IU/kg via SC injection twice weekly (every 3 to 4 days); May be self (or caregiver)-administered with proper training</td>
<td>Lyophilized powder for reconstitution; single-use vials containing 2,000 or 3,000 IU</td>
</tr>
<tr>
<td>lanadelumab-flyo (Takhzyro)</td>
<td>300 mg SC every 2 weeks; If the patient is attack-free for &gt; 6 months, a dose of 300 mg every 4 weeks may be considered; May be self-administered with proper training</td>
<td>300 mg/2 mL solution single-use vial; 300 mg/2 mL single-dose prefilled syringe</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ecallantide (Kalbitor)</td>
<td>30 mg SC administered as 10 mg/mL at 3 anatomical sites: abdomen, thigh, upper arm (site rotation not necessary); May repeat dose within a 24 hour period if attack persists; HCP-administered</td>
<td>10 mg/mL solution single-use vial (3 per carton)</td>
</tr>
<tr>
<td>icatibant (Firazyr)</td>
<td>30 mg SC abnormally over at least 30 seconds; Additional doses may be administered at interval of at least 6 hours if inadequate response or symptoms recur; No &gt; 3 injections should be administered in 24 hours; May be self-administered with proper training</td>
<td>30 mg/3 mL prefilled syringe†</td>
</tr>
<tr>
<td>pdC1-INH (Berinert)</td>
<td>20 IU/kg IV at a rate of 4 mL/min; Doses &lt; 20 IU/kg should not be given; A silicone-free syringe should be used for reconstitution and administration of Berinert; May be self-administered with proper training</td>
<td>Lyophilized powder for reconstitution; 500 IU/10 mL single-use vial</td>
</tr>
<tr>
<td>rhC1-INH (Ruconest)</td>
<td>50 IU/kg IV over 5 minutes; may repeat dose if attack symptoms persist; do not exceed 4,200 IU per dose; do not exceed 2 doses in a 24 hour period Body weight &lt; 84 kg: 50 IU/kg; Body weight ≥ 84 kg: 4,200 IU (2 vials); May be self-administered with proper training</td>
<td>Lyophilized powder for reconstitution; 2,100 IU/25 mL single-use vial</td>
</tr>
</tbody>
</table>

HCP = health care professional; SC = subcutaneously; IU = international units; IV = intravenous

* Available under brand name (Firazyr), as generic (icatibant), and as a branded generic (Sajazir™).

pdC1-INH (Berinert, Cinryze) and rhC1-INH (Ruconest) infusions should not be mixed with other medicinal products and should be administered in a separate infusion line.

pdC1-INH (Haegarda) preservative-free solution should be used within 8 hours of reconstitution

Lanadelumab-flyo (Takhzyro) solution should be stored refrigerated at 36°F to 46°F (2°C to 8°C) and be kept in its original carton in order to protect it from light.
CLINICAL TRIALS

Search Strategies

Studies were identified through searches performed on PubMed and review of information sent by manufacturers. Search strategy included the use of all brand names in this class. Randomized, comparative, controlled trials performed in the United States comparing agents within this class in an outpatient setting for the approved indications are considered the most relevant in this category. Studies included for analysis in the review were published in English, performed with human participants, and randomly allocated participants to comparison groups. In addition, studies must contain clearly stated, predetermined outcome measure(s) of known or probable clinical importance, use data analysis techniques consistent with the study question, and include follow-up (endpoint assessment) of at least 80% of participants entering the investigation. Using these criteria, numerous studies were found. Data were further excluded based on the following characteristics: formulation or drug not available in US, single-blind or single-dose study. Despite some inherent bias found in all studies, including those sponsored and/or funded by pharmaceutical manufacturers, the studies in this therapeutic class review were determined to have results or conclusions that do not suggest systematic error in their experimental study design. While the potential influence of manufacturer sponsorship and/or funding must be considered, the studies in this review have also been evaluated for validity and importance.

berotralstat (Orladeyo)

APeX-2 (NCT3485911): A multicenter, randomized, double-blind, placebo-controlled, parallel group study evaluated the efficacy of berotralstat for the prevention of angioedema attacks in patients ≥ 12 years of age with type I and II HAE.77,78 The study enrolled 121 adults and adolescents with HAE due to C1 inhibitor deficiency with a history of ≥ 2 HAE attacks within the 8 week lead in period. Patients were randomized into 1 of 3 parallel treatment arms (berotralstat 110 mg, berotralstat 150 mg, or placebo) orally once daily with food for 24 weeks. Patients discontinued other prophylactic HAE treatment prior to the study. Patients were allowed to use rescue treatment for breakthrough attacks. Study arms were comparable in terms of baseline characteristics with patients being primarily female and an average baseline HAE attack rate of approximately 3 attacks per month. A total of 70% of patients had a baseline attack rate of ≥ 2 attacks per month. The primary endpoint of the study was reduction in investigator-confirmed HAE attack rate during the 24-week treatment period which was double-blind. Of the 121 patients randomized, 120 patients received ≥ 1 dose of study drug. At both doses evaluated, berotralstat showed a statistically significant reduction in attack rate (110 mg: 1.65 attacks per month, p=0.024 versus placebo; 150 mg: 1.31 attacks per month, p<0.001 versus placebo; placebo: 2.35 attacks per month). The decrease in average attack rate started during the first month of treatment with berotralstat and continued through 24 weeks. Regardless of attack rate during the run-in period, the decreases in HAE attack rate were larger with berotralstat 150 mg and 110 mg compared to placebo. The proportion of patients with a ≥ 50% decrease in attacks across the 24 weeks was 58% in the 150 mg berotralstat arm (odds ratio [OR], 3.913; 95% confidence interval [CI], 1.507 to 10.164; p=0.005) and 51% in the 110 mg berotralstat arm (OR, 3.042; 95% CI, 1.183 to 7.821; p=0.021) compared with 25% of patients in the placebo arm. Authors concluded both doses of berotralstat (110 mg and 150 mg) resulted in reduction in HAE attack rates compared to placebo and were found to be generally well tolerated with the 150 mg dose exhibiting a more favorable benefit versus risk profile.
**C1 esterase inhibitors, plasma-derived (Berinert)**

IMPACT-1: The safety and efficacy of pdC1-INH were evaluated in a placebo-controlled, double-blind, parallel-group, clinical study that enrolled 124 patients who were experiencing an acute moderate to severe attack of abdominal or facial HAE.\(^{79,80}\) Age range of subjects was from 6 to 72 years. The time to onset of relief of symptoms was assessed based on patient questionnaires of individual symptoms and the severity of each symptom over time. Subjects were randomized into 3 groups to receive a single dose of pdC1-INH of 10 IU/kg or 20 IU/kg of body weight, or a single dose of placebo administered by slow IV infusion within 5 hours of a HAE attack. If sufficient relief of symptoms was not experienced by 4 hours after the infusion, study investigators had the option to give a blinded rescue dose as a second dose of pdC1-INH at 20 IU/kg for the placebo group, 10 IU/kg for the 10 IU/kg group, or placebo for the 20 IU/kg group. All subjects who received rescue medication were regarded as non-responders and the time to onset of symptom relief was set at 24 hours if a subject received any rescue medication (including rescue study medication, narcotic analgesics, non-narcotic analgesics, anti-emetics, open-label C1 inhibitor, androgens at increased dose, or fresh frozen plasma) between 5 hours before administration of blinded study medication until time to onset of relief. Subjects treated with pdC1-INH 20 IU/kg experienced a faster onset of symptom relief as compared to placebo (0.5 versus 1.5 hours, respectively; \(p=0.0025\)), regardless of the location of the attack (face or abdomen). The difference in the time to onset of relief from symptoms between the pdC1-INH 10 IU/kg group and the placebo group was not statistically significantly different. Within 60 minutes after the administration of study medication, 62.8% of subjects in the pdC1-INH 20 IU/kg group reported onset of symptom relief versus 26.2% in the placebo group. The median time to complete resolution of symptoms was significantly shorter with pdC1-INH 20 IU/kg compared with placebo (4.9 versus 7.8 hours, respectively; \(p=0.0237\)). Approximately 30% of subjects required rescue medication in the pdC1-INH 20 IU/kg group compared to about 55% in the placebo group.

**C1 esterase inhibitors, plasma-derived (Cinryze)**

A single randomized, double-blind, placebo-controlled multicenter cross-over study evaluated the safety and efficacy of pdC1-INH prophylaxis therapy to reduce the incidence, severity, and duration of HAE attacks.\(^{81}\) This study enrolled 24 HAE patients with a history of at least 2 HAE attacks per month. Age range in the study was 9 to 73 years. Patients were randomized to 1 of 2 treatment groups: either pdC1-INH prophylaxis for 12 weeks followed by 12 weeks of placebo prophylaxis or placebo prophylaxis for 12 weeks followed by 12 weeks of pdC1-INH prophylaxis. Doses were given every 3 to 4 days, approximately 2 times per week. Patients kept a daily record of any new angioedema symptoms that were not present the previous day. The efficacy determination was based on the comparison of the number of attacks during the 12-week period while receiving pdC1-INH versus placebo. Mean number of attacks was 6.1 for the study drug as compared to 12.7 for placebo (\(p<0.0001\)). Mean duration of HAE attacks reported was 2.1 days for pdC1-INH and 3.4 days for placebo. The number of days swelling was reported was 10.1 for pdC1-INH and 29.6 for placebo. Mean severity was less with the study drug, 1.3 versus 1.9, based on a 3-point scoring system (1=mild, 2=moderate, 3=severe).

**C1 esterase inhibitors, plasma-derived (Haegarda)**

COMPACT trial:\(^{82,83}\) The safety and efficacy of C1-INH, a nanofiltered, plasma-derived, C1 inhibitor preparation was established in a phase 3, double-blind, randomized, placebo-controlled, 32-week, cross over study in 90 patients with a diagnosis of type I or type II HAE. Patients with \(\geq 4\) attacks in a consecutive
2-month period within 3 months before study screening were included. Patients were randomly assigned to 1 of 4 treatment groups, with each involving two 16-week treatment periods. Patients received either 40 IU or 60 IU per kg of C1-INH, which was self-administered SC twice weekly followed by placebo, or vice versa. The primary efficacy endpoint was the number of angioedema attacks. The secondary efficacy endpoint was the proportion of patients who had a response and the number of times a rescue medication was used. A response was defined as a ≥ 50% reduction in the number of attacks while on C1-INH as compared with placebo. Of the 90 patients randomized to groups, 79 completed the study. Both doses of C1-INH, compared to placebo, reduced the incidence of attacks. The 40 IU group experienced 2.4 less attacks per month compared to placebo with a response rate of 76% (p<0.001) and the 60 IU group experienced 3.5 lesser attacks per month when compared to placebo (p<0.001) with a 90% response rate. Additionally, rescue medication utilization was also reduced compared to placebo. The 40 IU group only required rescue medication of 1.1 uses per month compared to placebo’s 5.6 uses per month (p=0.018). The 60 IU group only required 0.3 uses of rescue medication compared to placebo’s 3.9 uses (p<0.001). The severity of attacks in the treatment arms were also less severe. Adverse events were mild and similar across all study groups.

A multicenter, randomized, open-label, parallel-arm, active treatment-controlled extension (NCT02316353) of COMPACT was conducted to evaluate the long-term outcomes of C1-INH SC (Haegarda). The adult and pediatric patients enrolled (n=126) were required to have frequent angioedema attacks with symptomatic HAE type I or II and be either study treatment-naive or have completed the COMPACT study. Patients were randomized 1:1 to receive either 40 IU/kg or 60 IU/kg C1-INH SC twice per week with up-titration to optimize prophylaxis. Almost half of the participants enrolled in the extension had participated in the initial COMPACT study. Patients had a monthly attack rate of 4.3 in the 3 months prior to enrollment. Patients had a median age of 41 years (range, 8 to 72) years and were treated for an average of 1.5 years during the study with 35% of patients having > 2 years of exposure. The average steady-state C1-INH functional activity increased in both study arms (40 IU/kg: 52.0%; 60 IU/kg: 66.6%). The overall incidence of adverse events was comparable in both treatment groups (40 IU/kg: 11.3 events per patient-year; 60 IU/kg: 8.5 events per patient-year). The median annualized attack rates were 1.3 for the 40 IU/kg study arm and 1 for 60 IU/kg study arm, and the median rescue medication use was 0.2 and 0 times per year, respectively. There were 23 patients who received 60 IU/kg for > 2 years, and 19 of these patients (83%) were free from attacks during months 25 to 30 of treatment. Authors concluded that long-term replacement therapy with C1-INH SC is a safe and efficacious prophylactic therapy for patients with frequent HAE attacks.

**C1 esterase inhibitors, recombinant (Ruconest)**

The safety and efficacy of rhC1-INH in the treatment of HAE acute attacks were demonstrated in a placebo-controlled, double-blind, randomized study (Study 1). Supportive evidence of effectiveness is provided by a double-blind, randomized, placebo-controlled study (Study 2).

Study 1: A double-blind, placebo-controlled trial that included an open-label extension evaluated the efficacy and safety of rhC1-INH 50 IU/kg in the treatment of acute HAE attacks in adults and adolescents (age range of 17 to 69 years). Patients were randomized to receive rhC1-INH 50 IU/kg (n=44) or placebo (n=31). The primary efficacy endpoint was the time to onset of symptom relief as documented by patient-reported questionnaires. Primary efficacy was assessed by patient responses on a Treatment Effect Questionnaire (TEQ). Rescue medication was allowed for patients who had no symptom improvement at 4 hours after study drug administration, or earlier if life-threatening oropharyngeal-
laryngeal angioedema symptoms occurred. If a patient required rescue medication prior to achieving initial relief of symptoms, the time to initial relief of symptoms was recorded as the last time the TEQ was assessed prior to medication use. In the blinded phase, the median time to onset of symptom relief was statistically significantly shorter in patients treated with rhC1-INH compared to those treated with placebo (90 versus 152 minutes, respectively; \( p=0.031 \)). Median time to minimal symptoms was 303 minutes in rhC1-INH group compared to 483 minutes in the placebo group (\( p=0.078 \)). A lesser proportion of patients in the rhC1-INH group received rescue medication compared to the placebo group (11% versus 42%, respectively). Among patients who achieved relief within 4 hours, 27% (n=4) of patients in the placebo group had a relapse of their symptoms within 24 hours versus 3% (n=1) for the rhC1-INH group. Data from planned subgroup analyses in US patients showed that the median time to onset of symptom relief with persistence was 98 minutes for those receiving rhC1-INH (n=22) and 90 minutes for those receiving placebo (n=16). Median time to onset of symptom relief for non-US patients receiving rhC1-INH (n=22) was 90 minutes and 334 minutes for those receiving placebo (n=15). In addition, analysis of gender subgroups suggested a greater treatment response in men than women. The median time to onset of symptom relief was 113 minutes for women receiving rhC1-INH (n=28) compared to women receiving placebo of 105 minutes (n=19). In men, these values were 75 minutes (n=16) and 480 minutes (n=12), respectively. No explanations for the regional or gender subgroup responses were found; however, it was noted that there was a larger-than-expected placebo response among US women.

In Study 2 (North American controlled trial), patients ranging in age from 17 to 66 years were randomized to receive a single dose of either rhC1-INH 50 IU/kg (n=12), rhC1-INH 100 IU/kg (n=13), or placebo (n=13). The efficacy of rhC1-INH in the treatment of acute HAE attacks was demonstrated by a significantly shorter time to onset of symptom relief based on the Visual Analogue Assessment Scores (VAS). A VAS decrease of at least 20 mm as compared to baseline with persistence of improvement at 2 consecutive time points was deemed as onset of symptom relief.

ecallantide (Kalbitor)

EDEMA-3: The safety and efficacy of ecallantide were assessed in a randomized, double-blind, placebo-controlled trial of 72 patients with HAE assigned to receive ecallantide or placebo for acute attacks. The primary efficacy endpoint was measured with the Treatment Outcome Score (TOS), a measure of symptom response at 4 hours after dose administration; a value > 0 reflected an improvement in symptoms from baseline. The key secondary efficacy endpoint was the change from baseline in Mean Symptom Complex Severity (MSCS) at 4 hours after the dose was administered. Patients treated with ecallantide experienced a significantly greater TOS than patients treated with placebo (63 versus 36, respectively; \( p=0.045 \)) and a significantly greater decrease from baseline in the MSCS than placebo (-1.1 versus -0.6, respectively; \( p=0.041 \)). In addition, 36% of patients in the placebo group required medical intervention to treat unresolved symptoms within 24 hours compared to 14% in the ecallantide group.

EDEMA-4: The safety and efficacy of ecallantide were assessed in a randomized, double-blind, placebo-controlled trial of 96 HAE patients assigned to receive ecallantide 30 mg SC or placebo for acute attacks of HAE. The primary endpoint was the change from baseline in MSCS score at 4 hours, and the key secondary endpoint was TOS at 4 hours. Patients treated with ecallantide experienced a significantly greater decrease from baseline in the MSCS than placebo (-0.8 versus -0.4, respectively; \( p=0.01 \)) and a significantly greater TOS than patients with placebo (53 versus 8, respectively; \( p=0.003 \)). At 24 hours, patients treated with ecallantide also reported a greater decrease from baseline in the MSCS than placebo (-1.5 versus -1.1, respectively; \( p=0.04 \)) and a greater TOS (89 versus 55, respectively; \( p=0.03 \)).
icatibant (Firazyr)

FAST-1 & 2:92 The efficacy and safety of icatibant 30 mg SC injection was evaluated in 2 phase 3 randomized, double-blind, controlled clinical trials in patients with HAE who presented within 6 hours of an acute attack with cutaneous or abdominal symptoms. In FAST-1, 56 patients received either icatibant or placebo; in FAST-2, 74 patients received icatibant or oral tranexamic acid 3 g once daily for 2 consecutive days. The primary efficacy endpoint in both trials was the median time to clinically significant relief of the index symptom, which was defined as the symptom (cutaneous swelling, cutaneous pain, or abdominal pain) with the highest score on the VAS measured prior to study drug administration. Abdominal pain was the index symptom for patients experiencing a combination of all 3 symptoms. In FAST-1, the time to clinically significant relief was not statistically significant between the icatibant group and placebo group (2.5 versus 4.6 hours, respectively; p=0.14). Although, as assessed by the patient and the investigator, the median time to first symptom improvement was significantly shorter in the icatibant group compared with the placebo group (0.8 hour versus 16.9 hours, respectively; p<0.001; and 1 hour versus 5.7 hours, respectively; p<0.001). In the FAST-1 study, 3 patients in the icatibant group and 13 in the placebo group needed rescue medication. In FAST-2, primary endpoint was reached in 2 hours for icatibant and 12 hours for tranexamic acid; the difference was statistically significant (p<0.001). No icatibant-related serious adverse events were reported.

FAST 3:93 In a randomized, placebo-controlled, double-blind, parallel-group study of 98 adults with HAE, patients received either a single dose of icatibant 30 mg or placebo by SC injection, given within 6 hours of onset of HAE symptoms. Patients with severe laryngeal attacks of HAE received open-label icatibant 30 mg. The primary endpoint was assessed with a VAS that included average assessments of skin swelling, skin pain, and abdominal pain. The median time to a response, defined as at least a 50% reduction from the pretreatment composite 3-item VAS score, for patients with cutaneous or abdominal attacks treated with icatibant, was 2 hours compared to 19.8 hours for placebo-treated patients (p<0.001). In addition, the median time to almost complete symptom relief was 8 hours for icatibant and 36 hours for placebo. Seven percent of patients in the icatibant group received rescue medication versus 40% in the placebo group.

lanadelumab-flyo (Takhzyro)

HELP:94 The HELP trial was a multicenter, double-blind, placebo-controlled, parallel-group study that included 125 patients ≥ 12 years of age with type I or II HAE who experienced at least 1 confirmed HAE attack per 4 weeks during the study run-in period (52% of patients had ≥ 3 attacks/month at run-in). Sixty-five percent of patients had a history of laryngeal attacks, and 56% had been on long-term HAE prophylaxis. At baseline, the mean number of monthly attacks was 3.7. Patients were stratified by baseline attack rate and randomized (3:2:2:2) to placebo or 1 of 3 doses of lanadelumab-flyo: 150 mg every 4 weeks, 300 mg every 4 weeks, or 300 mg every 2 weeks. Doses were administered SC for 26 weeks. Patients ≥ 18 years of age were required to discontinue other prophylactic HAE medications prior to entering the study; however, all patients were allowed to use rescue medications for treatment of breakthrough HAE attacks. The primary efficacy endpoint was the number of HAE attacks during the treatment period, which was 1.97, 0.48, 0.53, and 0.26 in the placebo and lanadelumab-flyo 150 mg every 4 weeks, 300 mg every 4 weeks, or 300 mg every 2 weeks groups, respectively. This translated to a 76%, 73%, and 87% reduction in attacks for the respective lanadelumab-flyo groups compared to placebo (p<0.001 for all compared to placebo). This percent reduction was the same or slightly higher in the intent-to-treat analysis (81%, 74%, and 87%, respectively). In addition, fewer average number of
attacks in the lanadelumab-flyo groups required acute treatment compared to the placebo group (0.31, 0.42, and 0.21 for lanadelumab-flyo groups, respectively, and 1.64 for placebo). The lanadelumab-flyo 150 mg dose is not FDA approved. Prespecified exploratory endpoints included the percentage of patients who achieved threshold reductions in HAE attacks. The percentage of patients who were attack-free during the 26-week treatment period was 39%, 44%, and 31% in the lanadelumab-flyo 150 mg every 4 week, 300 mg every 2 week, and 300 mg every 4 week groups, respectively, compared to 2% of placebo patients. A ≥ 50% reduction in HAE attack rate was observed in 100% of patients on 300 mg every 2 weeks or every 4 weeks and 89% on 150 mg every 4 weeks, compared to 32% of placebo patients. Patients who completed the HELP trial were eligible to enter an open-label extension trial. Independent of treatment group in the original study, all patients received a single dose of lanadelumab-flyo 300 mg upon entering the extension trial and were followed until the first HAE attack was experienced. Four weeks after the dose, approximately 80% of patients who had been in the 300 mg every 2 weeks group (n=25) remained attack-free. After the first HAE attack, all patients were given lanadelumab-flyo 300 mg every 2 weeks.

**SUMMARY**

Hereditary angioedema (HAE) is a rare genetic disorder that results in low levels of endogenous or functional C1 esterase inhibitor (C1-INH). HAE is characterized by recurrent episodes of subcutaneous or submucosal edema involving the skin or mucosal tissues of the upper respiratory and GI tracts. Accurate diagnosis of HAE due to C1INH deficiency is critical for proper treatment.

Plasma-derived concentrates of human plasma-derived C1-INH (Berinert, Cinryze) and a recombinant analogue of C1-INH (Ruconest) are available as IV injections, and human plasma-derived C1-INH (Haegarda) is available as a subcutaneous injection. Ecallantide (Kalbitor) is a selective inhibitor of the plasma protein, kallikrein, and is administered subcutaneously. Lanadelumab-flyo (Takhzyro) is the second kallikrein inhibitor, but the only monoclonal antibody, and is administered subcutaneously. Berotralstat (Orladeyo) is the third kallikrein inhibitor and is administered orally once daily. Icatibant (Firazyr) is a selective synthetic bradykinin B2 receptor antagonist and is also administered subcutaneously. All agents, with the exception of ecallantide, may be self-administered with proper training. Cinryze, Haegarda, Takhzyro, and Orladeyo are FDA-approved for prophylactic use, while the remaining agents are indicated for treatment of HAE attacks. Thromboembolic events (TE) have been reported in patients receiving C1-INH. Although pasteurized and purified, there is a small potential for transmission of infection since C1-INH agents (Berinert, Cinryze, Haegarda) are derived from human blood. Recombinant C1-INH (Ruconest) does not have this precaution. Due to the potential for negative cardiovascular effects, icatibant (Firazyr) should be used with caution in patients with unstable angina, acute coronary ischemia, and in the weeks following a stroke. Headache and nausea are common adverse effects reported. Injection site reactions are most commonly reported with use of icatibant (Firazyr).

While all agents have established effectiveness in clinical trials, no head-to-head studies have been performed for the agents in the review. Per current clinical guidelines, plasma-derived C1-INH (Berinert, Cinryze, Haegarda), recombinant human C1-INH (Ruconest), ecallantide (Kalbitor), and icatibant (Firazyr) are all considered first-line therapy for the treatment of HAE attacks; one agent is not preferred over another. Furthermore, it should be noted that while the C1-INH agents and ecallantide may treat adolescents and adults, plasma-derived C1-INH (Berinert) is currently FDA-approved to treat both adults and all ages within the pediatric population. Cinryze and Haegarda are currently FDA-approved for
routine prophylaxis to prevent HAE attacks in ages ≥ 6 years. Orladeyo is FDA-approved for routine prophylaxis to prevent HAE attacks in ages ≥ 12 years.

REFERENCES

3 Haegarda [package insert]. Kankakee, IL; CSL Behring; September 2020.
4 TakHZyro [package insert]. Lexington, MA; Shire; February 2022.
7 Berinert [package insert]. Kankakee, IL; CSL Behring; September 2021.
8 Ruconest [package insert]. Raleigh NC; Santarus; April 2020.
30 Berinert [package insert]. Kankakee, IL; CSL Behring; September 2021.
31 Ruconest [package insert]. Raleigh NC; Santarus; April 2020.
32 Kalbitor [package insert]. Burlington, MA; Dyax; December 2020.
35 TakHZyro [package insert]. Lexington, MA; Shire; February 2022.
38 Berinert [package insert]. Kankakee, IL; CSL Behring; September 2021.
43 TakHZyro [package insert]. Lexington, MA; Shire; February 2022.
47 Ruconest [package insert]. Raleigh NC; Santarus; April 2020.
51 Takhzyro [package insert]. Lexington, MA; Shire; February 2022.
54 Berinert [package insert]. Kankakee, IL; CSL Behring; September 2021.
59 Takhzyro [package insert]. Lexington, MA; Shire; February 2022.
63 Ruconest [package insert]. Raleigh NC; Santarus; April 2020.
64 Kalbitor [package insert]. Burlington, MA; Dyax; December 2020.
67 Takhzyro [package insert]. Lexington, MA; Shire; February 2022.
70 Berinert [package insert]. Kankakee, IL; CSL Behring; September 2021.
71 Ruconest [package insert]. Raleigh NC; Santarus; April 2020.
74 Haegarda [package insert]. Kankakee, IL; CSL Behring; September 2020.
75 Takhzyro [package insert]. Lexington, MA; Shire; February 2022.
82 Haegarda [package insert]. Kankakee, IL; CSL Behring; September 2020.
84 Haegarda [package insert]. Kankakee, IL; CSL Behring; September 2020.
86 Ruconest [package insert]. Raleigh NC; Santarus; April 2020.
87 Ruconest [package insert]. Raleigh NC; Santarus; April 2020.
89 Ruconest [package insert]. Raleigh NC; Santarus; April 2020.
94 Takhzyro [package insert]. Lexington, MA; Takeda; February 2022.